The U.S. Food and Drug Administration (FDA) issues a warning letter to Eugia Pharma Specialities, a subsidiary of Aurobindo Pharma, covering a formulation manufacturing unit in Telangana. The letter follows a period of regulator scrutiny of the facility.
According to company statements reported by outlets, the FDA inspects the facility (Unit-I) from February 16 to February 27, 2026. After the inspection, the facility had received four observations and an Official Action Indicated (OAI) status from the regulator. The warning letter reflects the FDA’s assessment of the issues identified during the inspection.
While reporting focuses on the same inspection timeline and regulatory outcome, outlets differ in emphasis. One source highlights the existence of the prior four observations and OAI status, while another underscores the inspection dates and that the company had informed it had undergone the FDA inspection. Both describe the warning letter as the latest step in the FDA’s compliance process related to the Telangana manufacturing site.
